Pacific Biosciences of California (NASDAQ:PACB) Shares Gap Up – Time to Buy?

Pacific Biosciences of California, Inc. (NASDAQ:PACB – Get Free Report) gapped up before the market opened on Wednesday. The stock had previously closed at $1.82, but opened at $1.89. Pacific Biosciences of California shares last traded at $1.9840, with a volume of 1,375,868 shares trading hands.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on PACB. Barclays lifted their price target on Pacific Biosciences of California from $1.25 to $2.00 and gave the stock an “underweight” rating in a research note on Thursday, November 5th. Piper Sandler reiterated a “neutral” rating and set a $3.00 price objective (up from $2.00) on shares of Pacific Biosciences of California in a research report on Thursday, November 5th. Wall Street Zen raised Pacific Biosciences of California from a “sell” rating to a “hold” rating in a report on Saturday, November 7th. UBS Group dropped their target price on Pacific Biosciences of California from $3.05 to $2.70 and set a “neutral” rating for the company in a research report on Monday, November 9th. Finally, Weiss Ratings raised Pacific Biosciences of California from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, October 13th. Three investment analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Pacific Biosciences of California presently has a consensus rating of “Reduce” and an average price target of $2.57.

View Our Latest Stock Report on PACB

Pacific Biosciences of California Stock Performance

The stock’s 50 day moving average price is $2.03 and its 200-day moving average price is $1.60. The company has a market cap of $599.26 million, a PE ratio of -4.56 and a beta of 2.21.

Pacific Biosciences of California (NASDAQ:PACB – Get Free Report) last issued its earnings results on Wednesday, November 4th. The biotechnology company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.02. The company had revenue of $40.56 million for the quarter, compared to analysts’ expectations of $39.31 million. Pacific Biosciences of California had a negative net margin of 81.31% and a negative return on equity of 5,752.12%. On average, analysts anticipate that Pacific Biosciences of California, Inc. will post -0.51 EPS for the current year.

Insider Activity

In other news, insider James Gibson, II sold 661,815 shares of the firm’s stock in a transaction dated Tuesday, October 6th. The stock was sold at an average price of $3.11, for a total transaction of $2,058,244.65. Following the transaction, the insider directly owned 1,083,848 shares of the company’s stock, valued at approximately $3,370,767.28. This trade represents a 37.91% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 3.70% of the company’s stock.

Institutional Investors Weigh In On Pacific Biosciences of California

Several institutional investors have recently bought and sold shares of the stock. BlackRock Inc. bought a new position in Pacific Biosciences of California during the 2nd quarter worth approximately $54,330,000. Bank of America Corp DE purchased a new position in Pacific Biosciences of California in the 2nd quarter worth approximately $2,265,000. Hhlr Advisors LTD. bought a new stake in Pacific Biosciences of California in the second quarter valued at approximately $1,544,000. Bank of New York Mellon Corp bought a new stake in Pacific Biosciences of California in the second quarter valued at approximately $1,290,000. Finally, Man Group plc purchased a new stake in shares of Pacific Biosciences of California during the second quarter valued at approximately $1,004,000.

Pacific Biosciences of California Company Profile

(Get Free Report)

Pacific Biosciences of California, or PacBio, develops and sells DNA sequencing systems and related products for life science research and clinical applications. The company is known for its single-molecule real-time (SMRT) sequencing technology, which produces long reads that can help researchers study complex regions of the genome and identify genetic variations. Its portfolio includes HiFi sequencing systems such as the Revio and Vega platforms, along with instruments, consumables, software and services used to prepare, sequence and analyze genetic samples.

Featured Articles

Receive News & Ratings for Pacific Biosciences of California Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences of California and related companies with MarketBeat.com's FREE daily email newsletter.